XML 102 R84.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) - Designated as Hedging Instrument [Member] - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Comprehensive Income [Member]      
Derivative [Line Items]      
Other comprehensive income (loss) $ (508) $ 91 $ (270)
Financial expenses [Member]      
Derivative [Line Items]      
Financial expenses, net 981 1,057 966
Cross Currency Swap Cash Flow Hedge [Member] | Other Comprehensive Income [Member]      
Derivative [Line Items]      
Other comprehensive income (loss) [1] 1 1 0
Cross Currency Swap Cash Flow Hedge [Member] | Financial expenses [Member]      
Derivative [Line Items]      
Financial expenses, net [1] $ (8) $ (11) $ 0
[1] On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million.